VIVUS, Inc. (NASDAQ:VVUS)
CAPS Rating:
A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.
RSS Headlines
Fool UK
Recs
I believe the scrips will pick up as distribution is improved. The obesity patients will choose a riskier Qsymia over a safer less effective Belviq.